Nemkova S A, Semenov D V, Petrova E A, Savchenko D V, Zavadenko N N, Vozvyshaeva M Yu
Pirogov Russian National Research Medical University, Moscow, Russia.
Russian State University of Sociology, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(7):27-34. doi: 10.17116/jnevro201911907127.
To study the efficacy of recognan (citicoline) in the treatment of cognitive, emotional, autonomic, asthenic disorders in patients with asthenic syndrome.
Thirty-eight subjects (17 men and 41 women), mean age 27.75±12.05 years, with asthenic syndrome (ICD-10 F48.0 - Neurasthenia) were studied. The sample was randomized into 2 subgroups: the main group (n=20) received oral therapy with recognan (100 mg in 1 ml) for 30 days, while the daily dosage was 500 mg (5 ml). In the control group (n=18), no drug therapy was performed. Patient's state was assessed with a large battery of psychological tests and psychometric scales. The follow-up period was 30 days. All participants were examined three times (initially, in the middle of the study (day 15), in the end of the study (day 30)).
Asthenic syndrome was detected in 100% of the patients (total asthenia was noted in 70%, decreased activity in 70%, decreased motivation in 40%, physical asthenia in 45%, mental asthenia in 50%). Recognan (citicoline), used for 2 weeks or one month, has a positive effect on the compensation of autonomic, asthenic cognitive and emotional disorders and increases stress resilience of the patients.
研究胞磷胆碱钠（可尼丁）治疗虚弱综合征患者认知、情感、自主神经及虚弱性障碍的疗效。
对38名年龄平均为27.75±12.05岁、患有虚弱综合征（国际疾病分类第十版F48.0 - 神经衰弱）的受试者（17名男性和21名女性）进行研究。样本被随机分为2个亚组：主要组（n = 20）接受口服胞磷胆碱钠（100毫克/1毫升）治疗30天，每日剂量为500毫克（5毫升）。对照组（n = 18）未进行药物治疗。通过大量心理测试和心理测量量表评估患者状态。随访期为30天。所有参与者接受三次检查（最初、研究中期（第15天）、研究结束时（第30天））。
100%的患者检测出虚弱综合征（70%出现全身虚弱，70%活动减少，40%动机降低，45%身体虚弱，50%精神虚弱）。使用2周或1个月的胞磷胆碱钠（可尼丁）对自主神经、虚弱性认知及情感障碍的代偿有积极作用，并提高患者的应激恢复能力。
